Abiopharma

🔍 Scanlon Jennifer F. (Executive)

Company: UL Solutions Inc. (ULS)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Acquired 21,413 shares of Class A Common Stock (Direct)
  Date: 2026-05-01 | Code: M | equity_swap_involved: false | shares_owned_after: 209,687.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 9,486 shares of Class A Common Stock at $91.6 per share (Direct)
  Date: 2026-05-01 | Code: F | equity_swap_involved: false | shares_owned_after: 200,201.00 | transaction_form_type: 4
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-05-01 | Code: H | nature_of_ownership: By Family Trust | shares_owned_after: 89,285.00
• Sold 21,413 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-01 | Code: M | equity_swap_involved: false | shares_owned_after: 21,422.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2, F3

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
• F2: The restricted stock units vest in three equal installments on the first, second and third anniversaries of May 1, 2024.
• F3: Includes restricted stock units and all dividend equivalent rights that have accrued on such restricted stock units to date.